Article PDF
Avoid common mistakes on your manuscript.
Références
Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21): 1182–1186
Folkman J (1972) Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 175(3): 409–416
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1): 57–70
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5): 646–674
Hurwitz H, Fehrenbacher L, Cartwright T, et al. (2003) Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc Am Soc Clin Oncol 22: 2003 (abstr 3646)
Merwin RM, Algire GH (1956) The role of graft and host vessels in the vascularization of grafts of normal and neoplastic tissue. J Natl Cancer Inst 17(1): 23–33
Yang JC, Haworth L, Sherry RM, et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349(5): 427–434
Author information
Authors and Affiliations
About this article
Cite this article
Vignot, S. Angiogenèse et cancer: une cible en mouvement. Oncologie 14, 197–198 (2012). https://doi.org/10.1007/s10269-012-2149-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10269-012-2149-6